What is William Blair’s Estimate for VRTX Q2 Earnings?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Stock analysts at William Blair issued their Q2 2025 EPS estimates for shares of Vertex Pharmaceuticals in a research report issued on Tuesday, May 6th. William Blair analyst M. Minter expects that the pharmaceutical company will post earnings per share of $3.95 for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share. William Blair also issued estimates for Vertex Pharmaceuticals’ Q3 2025 earnings at $4.16 EPS and Q4 2025 earnings at $4.54 EPS.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing analysts’ consensus estimates of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.85 billion. During the same quarter last year, the business posted $4.76 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year.

VRTX has been the subject of a number of other reports. Royal Bank of Canada increased their target price on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the company a “sector perform” rating in a research report on Tuesday. The Goldman Sachs Group reissued a “buy” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday. Truist Financial upped their price target on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $535.00 price objective on shares of Vertex Pharmaceuticals in a report on Tuesday. Finally, Morgan Stanley upped their price objective on shares of Vertex Pharmaceuticals from $462.00 to $464.00 and gave the company an “equal weight” rating in a report on Tuesday. Thirteen investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $515.04.

Vertex Pharmaceuticals Price Performance

VRTX opened at $434.82 on Thursday. The firm has a market cap of $111.78 billion, a P/E ratio of -197.65, a PEG ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. Vertex Pharmaceuticals has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The firm has a 50-day moving average of $491.04 and a 200 day moving average of $466.58.

Institutional Trading of Vertex Pharmaceuticals

Several large investors have recently bought and sold shares of VRTX. Meeder Advisory Services Inc. lifted its stake in shares of Vertex Pharmaceuticals by 13.4% in the 1st quarter. Meeder Advisory Services Inc. now owns 6,360 shares of the pharmaceutical company’s stock valued at $3,083,000 after purchasing an additional 753 shares during the period. Fiera Capital Corp boosted its holdings in shares of Vertex Pharmaceuticals by 5.7% during the 1st quarter. Fiera Capital Corp now owns 7,092 shares of the pharmaceutical company’s stock valued at $3,438,000 after buying an additional 382 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC grew its position in shares of Vertex Pharmaceuticals by 6.6% in the 1st quarter. Pinnacle Wealth Management Advisory Group LLC now owns 731 shares of the pharmaceutical company’s stock worth $354,000 after buying an additional 45 shares during the period. Fielder Capital Group LLC bought a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth about $258,000. Finally, Foundations Investment Advisors LLC lifted its position in Vertex Pharmaceuticals by 17.7% during the 1st quarter. Foundations Investment Advisors LLC now owns 993 shares of the pharmaceutical company’s stock valued at $481,000 after acquiring an additional 149 shares during the period. 90.96% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP David Altshuler sold 3,231 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This represents a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 310 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total value of $142,547.30. Following the transaction, the executive vice president now directly owns 64,021 shares of the company’s stock, valued at $29,438,776.43. The trade was a 0.48 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 in the last ninety days. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.